Skip to main content

Table 1 Summary of baseline characteristics of 53 Caucasian postmenopausal women

From: Organic anion transporting polypeptides OATP1B1 and OATP1B3 and their genetic variants influence the pharmacokinetics and pharmacodynamics of raloxifene

  mean (SD) Range
Age (year) 59.7 (6.2) 39.0 – 69.0
Years postmenopausal (year) 13.1 (6.9) 5.0 – 38.0
BMI (kg/m 2 ) 25.6 (3.4) 18.9 – 34.9
SBP (mmHg) 143.4 (17.8) 105.0 – 190.0
DBP (mmHg) 85.5 (10.0) 60.0 – 105.0
BALP (μg/L) 12.2 (5.3) 4.9 – 29.1
OC (ng/mL) 33.5 (11.3) 10.0 – 60.3
CTX (ng/mL) 0.52 (0.19) 0.12 – 0.89
BUA (dB/MHz) 54.8 (11.5) 33.8 – 85.9
SOS (m/s) 1,513.5 (21.1) 1,464.4 – 1,562.6
QUI 72.0 (12.7) 43.9 – 104.9
BMD-HIP(g/cm 2 ) 0.727 (0.096) 0.472 – 0.910
BMD-FN(g/cm 2 ) 0.627 (0.076) 0.420 – 0.840
BMD-LS (g/cm 2 ) 0.759 (0.071) 0.586 – 0.950
HOL (mmol/L) 5.85 (0.78) 4.31 – 7.37
HDL (mmol/L) 1.65 (0.31) 1.19 – 2.36
LDL (mmol/L) 3.53 (0.67) 2.17 – 4.81
TG (mmol/L) 1.50 (0.72) 0.67 – 4.03
  1. BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; BALP, serum bone-specific alkaline phosphatase; OC, serum osteocalcin; CTX, serum C-terminal telopeptide fragments of type I collagen; BUA, broadband ultrasound attenuation; SOS, heel speed of sound; QUI, quantitative ultrasound index; BMD-HIP, bone mineral density of total hip; BMD-FN, bone mineral density of femoral neck; BMD-LS, bone mineral density of lumbar spine.